ESGO State of the Art Conference / December 14-16, 2020
Copenhagen, Denmark
Preliminary Program
|
| |
| Monday, December 14 |
| |
|
|
| 10.00-11.00 |
Cervical cancer primary therapy (Surgery & ChemoRad)  |
| |
Chairs: David Cibula, Czech Republic & Jacob Lindegaard, Denmark |
|
| 10.00-10.20 |
Update on Cervical cancer surgery |
David Cibula, Czech Republic |
| 10.20-10.40 |
Update on Cervical cancer chemorad |
Jacob Lindegaard |
| 10.40-11.00 |
Panel discussion |
David Cibula (moderator), Jacob Lindegaard, Ignace Vergote, Christina Fotopoulou |
| |
|
|
| 11.00-12.00 |
Industry symposium supported by Clinical Care Options |
|
| |
|
|
| 12.00-13.00 |
Cervical cancer – Metastatic and relapsed disease |
| |
Chairs: Nicole Concin, Austria & Sandro Pignata, Italy |
| 12.00-12.05 |
Set up the case |
Nicole Concin, Austria |
| 12.05-12.25 |
State of the art lecture |
Ana Oaknin, Spain |
| 12.25-13.00 |
Panel discussion |
Sandro Pignata (moderator), Ana Oaknin, Nicole Concin, Maria Bjurberg, Nicoletta Colombo |
| |
|
|
| 13.00-13.45 |
Lunch break |
|
| |
|
|
| 13.45-14.45 |
Industry symposium supported by GSK |
|
| |
|
|
| 14.45-15.15 |
Company sponsored talk supported by Genmab
|
|
| |
|
|
| 15.15-15.35 |
Coffee break |
|
| |
|
|
| 15.35-16.00 |
Welcome and opening |
| 15.35-15.45 |
Welcome from ESGO president |
Philippe Morice, France |
| 15.45-16.00 |
Welcome from ESGO SoA 2020 chairs |
Mansoor Raza Mirza, Denmark & Christina Fotopoulou, UK |
| |
|
|
| 16.00-17.30 |
ENGOT: Improving patients´ outcome through clinical trials |
| |
Chairs: Antonio González Martín, Spain & Mansoor Raza Mirza, Denmark |
| 16.00-16.15 |
ENGOT collaboration |
Antonio González Martín, Spain |
| 16.15-16.30 |
Decade of achievements |
Mansoor Raza Mirza, Denmark |
| 16.30-16.45 |
Importance of translational research and bio-banking for personalized treatment |
Ioana Braicu, Germany |
| 16.45-17.30 |
Panel discussion |
Sandro Pignata, Andreas du Bois, Eric Pujade-Lauraine, Ignace Vergote, Ioana Braicu, Antonio González Martín, Mansoor Raza Mirza |
| |
|
|
| 17.30-18.30 |
Three minute thesis |
| |
Chairs: Philippe Morice, France & Jonathan Ledermann, UK |
| |
Introduction |
|
| |
Assessing trends in stage and outcomes of uterine cervix cancer in an opportunistic screening setting. |
Francisco Jose Candido dos Reis, Brazil |
| |
Recurrence and survival after laparoscopy versus laparotomy in early stage endometrial cancer: Follow-up five years after a randomised trial |
Marian J.E. Mourits, Netherlands |
| |
Long-term results of neoadjuvant dose-dense platinum-based chemotherapy in patients with locally advanced cervical cancer |
Elena Ulrikh, Russia |
| |
Effect of sentinel lymph node biopsy on upper limb function in women with early breast cancer: A systematic review of clinical trials |
Francisco Jose Candido dos Reis, Brazil |
| |
Patient-reported outcomes (PROS) in patients (PTS) receiving NIRAPARIB in the PRIMA/ENGOT-OV26/GOG-3012 trial |
Johanna U. Maenpaa, Finland |
| |
Efficacy and safety of NIRAPARIB in older patients (PTS) with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial |
Hanna Dahlstrand, Sweden |
| |
Maintenance OLAPARIB in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: Subgroup analysis by risk in the phase III SOLO1 study |
Nicoletta Colombo, Italy |
| |
Fertility-sparing treatment in advanced borderline ovarian tumors. An analysis from the MITO14 study database |
Francesca Falcone, Italy |
| |
Elucidating resistance mechanism to parp inhibitors for the development of novel therapeutic approaches in high-grade serous ovarian cancer |
Hagen Kulbe, Germany |
| |
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch gynecological oncology audit (DGOA). |
Nishita Baldewpersad Tewarie, Netherlands |
| |
Treatment strategies and survival of women with sex cord stroma cell tumours – an analysis of the AGO-CORSETT database |
Maximilian Klar, Germany |
| |
Novel 3D model systems to assess heterogeneity in response to platinum therapy in high grade serous ovarian cancer |
Jennifer Ploski, UK |
| |
|
|
| 18.30-18.35 |
Introduction to next days programme |
Philippe Morice, France |
| |
|
|
| Tuesday, December 15 |
| |
|
|
| 8.00-8.15 |
Ovarian cancer guidelines |
|
| 8.00-8.15 |
ESGO-ESMO ovarian cancer guidelines |
Nicoletta Colombo, Italy |
| |
|
|
| 8.15-9.15 |
Ovarian cancer surgery |
| |
Chairs: Christina Fotopoulou, UK & Andreas du Bois, Germany |
| 8.15-8.20 |
Set up the case |
Luis Chiva, Spain |
| 8.20-8.40 |
State of the art lecture |
Andreas du Bois, Germany |
| 8.40-9.15 |
Panel discussion |
Christina Fotopoulou (moderator), Luis Chiva, Andreas du Bois, Ignace Vergote |
| |
|
|
| 9.15-10.15 |
Industry symposium sponsored by Novocure |
|
| |
|
|
| 10.15 -10.35 |
Coffee break |
|
| |
|
|
| 10.35-11.35 |
Ovarian first-line |
|
| |
Chairs: Philipp Harter, Germany & Eric Pujade-Lauraine, France |
| 10.35-10.40 |
Set up the case |
Philipp Harter, Germany |
| 10.40-11.00 |
State of the art lecture |
Eric Pujade-Lauraine, France |
| 11.00-11.35 |
Panel discussion |
Eric Pujade-Lauraine (moderator), Philipp Harter, Jonathan Ledermann, Mansoor Raza Mirza |
| |
|
|
| 11.35-12.35 |
Ovarian relapse; platinum an option |
| |
Chairs: Nicoletta Colombo, Italy & Isabelle Ray-Coquard, France |
| 11.35-11.40 |
Set up the case |
Isabelle Ray-Coquard, France |
| 11.40-12.00 |
State of the art lecture |
Jonathan Ledermann, UK |
| 12.00-12.35 |
Panel discussion |
Nicoletta Colombo (moderator), Isabelle Ray-Coquard, Jonathan Ledermann, Johanna Maenpaa, Eric Pujade-Lauraine |
| |
|
|
| 12.35-13.20 |
Lunch break |
|
| |
|
|
| 13.20-14.20 |
Industry symposium sponsored by Clinical Care Options
|
|
| |
|
|
| 14.20-15.20 |
Ovarian relapse; platinum not an option
|
| |
Chairs: Jalid Sehouli, Germany & Andres Poveda, Spain |
|
| 14.20-14.25 |
Set up the case |
Jalid Sehouli, Germany |
| 14.25-14.45 |
State of the art lecture |
Ignace Vergote, Belgium |
| 15.45-15.20 |
Panel discussion |
Andres Poveda (moderator), Jalid Sehouli, Ignace Vergote, Nicoletta Colombo |
| |
|
|
| 15.20-15.40 |
Coffee break |
|
| |
|
|
| 15.40-16.40 |
Industry symposium sponsored by GSK |
|
| |
|
|
| 16.40-18.10 |
Presidential session |
|
| |
Chairs: Philippe Morice, France & Mansoor Mirza, Denmark |
|
| 16.40-16.50 |
A randomised phase II study of NINTEDANIB (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC/ENGOT-OV36) |
Rosalind Glasspool, UK |
| 16.50-17.00 |
Significant variation in treatment and survival outcomes in stage 2-4 ovarian cancer in England: results from the national ovarian cancer feasibility audit pilot |
Sudha S Sundar, UK |
| 17.00-17.15 |
Succor cone: is it cervical conization a protective maneuver |
Enrique Chacón, Spain |
| 17.15-17.25 |
Impact of the covid pandemic on gynaecological cancer surgery – results from the covidsurg gynaecological cancer international study |
Sudha S Sundar, UK |
| 17.25-17.32 |
Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: Prima/ENGOT-ov26/GOG-3012 study |
Elena Ioana Braicu, Germany |
| 17.33-17.40 |
NIRAPARIB in patients with newly diagnosed advanced ovarian BRCAM cancer: A post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial |
Jacob Korach, Israel |
| 17.40-17.47 |
Early salpingectomy (tubectomy) with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy to improve quality of life in women with a BRCA1/2 pathogenic variant (TUBA study): A prospective multicenter preference trial |
Miranda P. Steenbeek, Netherlands |
| 17.48-17.55 |
Attitudes towards risk reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: A COHORT study |
Faiza Gaba, UK |
| 17.55-18.05 |
Increased institutional surgical experience in robot-assisted radical hysterectomy for early stage cervical cancer reduces recurrence rate. Results from a nationwide study. |
Linnea Ekdahl, Sweden |
| 18.05-18.10 |
Discussion |
|
| |
|
|
| 18.10-18.15 |
Introduction to next day programme |
Mansoor Raza Mirza, Denmark |
| |
|
|
| Wednesday, December 16 |
| |
|
|
| 8.00-10.00 |
Major advances in gynaecological cancers 2020 - Part II |
|
| |
Chairs: Luis Chiva, Spain & Mansoor Raza Mirza, Denmark |
| 8.00-8.20 |
The ABRAX trial and what next? |
David Cibula, Czech Republic |
| 8.20-8.40 |
Relapse surgery in ovarian cancer - Improving outcome of our patients |
Andreas du Bois, Germany |
| 8.40-9.00 |
Discussion |
|
| 9.00-9.20 |
Role of immunotherapy in gynaecological malignancies |
Antonio González Martín, Spain |
| 9.20-9.40 |
Advances in targeted therapy in gynaecological cancers |
Jonathan Ledermann, UK |
| 9.40-10.00 |
Discussion |
|
| |
|
|
| 10.00-10.20 |
Coffee break |
|
| |
|
|
| 10.20-10.45 |
NEW Endometrial cancer guidelines |
|
| 10.20-10.45 |
ESGO-ESTRO-ESP endometrial cancer guidelines - first public presentation |
Nicole Concin, Austria |
| |
|
|
| 10.45-11.45 |
Endometrial cancer surgery |
| |
Chairs: Denis Querleu, France & Christian Marth, Austria |
| 10.45-10.50 |
Set up the case |
Jalid Sehouli, Germany |
| 10.50-11.10 |
State of the art lecture |
Philippe Morice, France |
| 11.10-11.45 |
Panel discussion |
Christian Marth (moderator), Denis Querleu, Philippe Morice, Line Bjorge |
| |
|
|
| 11.45-12.45 |
Industry symposium sponsored by Intuitive Surgical |
|
| |
|
|
| 12.45-13.30 |
Lunch break |
|
| |
|
|
| 13.30-14.30 |
Endometrial cancer adjuvant therapy |
|
| |
Chairs: Mansoor Raza Mirza, Denmark & Philippe Morice, France |
| 13.30-13.35 |
Set up the case |
Remi Nout, Netherlands |
| 13.35-13.55 |
State of the art lecture |
Ketta Lorusso, Italy |
| 13.55-14.30 |
Panel discussion |
Philippe Morice (moderator), Mansoor Raza Mirza, Ketta Lorusso, Nicole Concin, Christian Marth, Remi Nout |
| |
|
|
| 14.30-15.00 |
Industry symposium sponsored by Eisai |
|
| |
|
|
| 15.00-15.20 |
Coffee break |
|
| |
|
|
| 15.20-16.20 |
Endometrial cancer (stage 4 & metastatic) |
|
| |
Chairs: Cagatay Taskiran, Turkey & Mansoor Raza Mirza, Denmark |
| 15.20-15.25 |
Set up the case |
Mansoor Raza Mirza, Denmark |
| 15.25-15.45 |
State of the art lecture |
Christian Marth, Austria |
| 15.45-16.20 |
Panel discussion |
Cagatay Taskiran (moderator), Mansoor Raza Mirza, Christian Marth, Nicoletta Colombo |
| |
|
|
| 16.20-17.35 |
Controversies |
| |
Chairs: Christina Fotopoulou, UK & David Cibula, Czech Republic |
| 16.20-16.35 |
Establishing SLN as standard of care in endometrial and cervical cancer? |
Denis Querleu, France |
| 16.35-16.50 |
Decision making processes, patients selection and allocation of healthcare resources in times of COVID-19 crisis |
Nadeem Abu-Rustum, USA |
| 16.50-17.05 |
Open vs MIS approach for radical hysterectomy and radical hysterectomy: limits and challenges |
Pedro Ramirez, USA |
| 17.05-17.35 |
Panel discussion |
David Cibula, Christina Fotopoulou, Denis Querleu, Nadeem Abu-Rustum, Pedro Ramirez |
| |
|
|
| 17.35-17.45 |
Closing remarks |
| 17.35-17.45 |
Closing and invitation to Prague congress |
Philippe Morice, France & Mansoor Raza Mirza, Denmark & Christina Fotopoulou, UK |
